

**ALKEM LABORATORIES LTD.**

Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, Mumbai - 400 013. Phone : 022-3982 9999, Fax : 022-2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN :- L00305MH1973PLC174201



23rd August, 2017

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. Scrip Symbol: ALKEM
---	---

Ref.: BSE letter dated 23/08/2017; No. *L/SURV/ONL/RV/ZS/(2017-2018)/116*
NSE letter dated 23/08/2017; No. *NSE/CM/Surveillance/ 6934*

Dear Sirs,

Sub.: Clarification to your letter dated 23rd August 2017 with respect to certain news appearing on www.moneycontrol.com on 23rd August 2017.

This is with respect to the above captioned subject. We would like to inform you that the Company receives approvals for new products from various international regulatory authorities from time to time and does not typically consider such events as a material event as per Regulation 30(3) and Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "**LODR Regulations**"). As per the policy for determination of materiality approved by the Board of Directors of the Company, all events / information are considered material if their financial impact on the Company is 5% or more of the gross turnover as per the last audited consolidated accounts of the Company. Since, receipt of the US FDA approval for the rhinitis drug, "Azelastine Hydrochloride Spray" does not amount to be a material event as mentioned above, the receipt of this approval was not required to be disclosed to the Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We would also like to inform you that information with respect to product related approvals granted by the US FDA is available on their website which is accessible to the public.

We wish to inform you that the Company has till date informed the Stock Exchanges of all material developments pursuant to Regulation 30 of the SEBI (Listing Regulation and Disclosure Requirements) Regulations, 2015 and accordingly we are not aware of any particular reason for increase in price of our scrip. The Company strives to ensure that the Stock Exchanges are informed about events and information in accordance with applicable regulatory requirements including the LODR Regulations.

Kindly take the same on your records.

Sincerely,

For Alkem Laboratories Limited


Manish Narang
President Legal, Company Secretary & Compliance Officer